The effectiveness of apatinib in the treatment of gastric adenocarcinoma

Gastric adenocarcinoma is a tumor that is not sensitive to chemotherapy, therefore, there are currently no recommendations for the treatment of patients in case of progression after two or more chemotherapy lines.

The presented study evaluated the efficacy and safety of apatinib, a new vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric adenocarcinoma or gastroesophageal compound with the ineffectiveness of the previous two or three chemotherapy lines.

The study included 267 patients from 32 centers in China who were randomized to receive oral apatinib, 850 mg once daily, or placebo.

The main endpoints were overall survival and progression-free survival.

Results There was a significant increase in median overall survival in the apatinib group compared with the placebo group (6.5 months compared to 4.7 months). Also, treatment with apatinib led to a significant lengthening of time without progression compared with the placebo group: 2.6 compared to 1.8 months.

Conclusion

The results of this study indicate a significant improvement in overall survival and progression-free time with an acceptable safety profile in the treatment of patients with advanced gastric cancer with apatinib, which makes it possible to consider this drug for use in developing resistance to two or more previous chemotherapy lines.

References

1. http: //www.univadis.ru/oncology-journals/335/Rol-apatinib... ...

2. Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; doi: 10.1200 / JCO.2015.63.5995